
Title: COMBINATION DRUG THERAPY FOR TREATING HYPERTENSION

Inventor(s): Carl J. Pepine et al. DOCKET NO.: 028685-0104

1/5


FIGURE 1



Inventor(s): Carl J. Pepine et al. DOCKET NO.: 028685-0104

2/5

FIGURE 2




There were no significant differences in systolic or diastolic blood pressure.

Inventor(s): Carl J. Pepine et al. DOCKET NO.: 028685-0104

3/5

FIGURE 3




The relative risk was 0.98 (95% confidence interval, 0.90-1.06).

		e RR (85% CI) Fevors CAS Fevors NCAS	0.98 (0.90-1.06)	0.98 (0.90-1.07)	0.99 (0.79-1.24)	0.89 (0.70-1.12)	1.00 (0.88-1.14)	1.03 (0.83-1.14)	0.6 0.8 1.0 1.2 1.4 RR (95% CJ)
		P Vetue	.57	.72	.9 6	8	Ą	6 2	
Non-Calcium Antagorist Strategy (NCAS) (n = 11309)		Rate per 1000 Patient-Years	37	8	ဟ	ស	1	ន	
		No. (%)	1150 (10.17)	893 (7.90)	153 (1.35)	148 (1.31)	431 (3.81)	709 (6.27)	
Calcium Antagonist Strategy (CAS) (n = 11267)	iratogy (CAS) (n=11267)	Rate per 1000 Patient-Years	88	8	J.C	4	4	7.	
Calcium Strates (n=1		No. (%)	1119 (9.83)	873 (7.75)	151 (1.34)	131 (1.18)	431 (3.83)	728 (6.44)	
			First Event	Death	Nonfatal Myocardial Infarction	Norrestal Stroke	Cardlovascutar-Related Death	Cardlovascular-Related Hospitalization	

CI indicates confidence interval; RR, relative risk. P value from Kaplan-Meier survival analysis.

Inventor(s): Carl J. Pepine et al. DOCKET NO.: 028685-0104

5/5



Other race/ethnicity indicates Asian or multiracial. All medical conditions were present at baseline. CI indicates confidence interval; RR, relative risk

FIGURE 5